RefSeq

Twist Bioscience Launches Portfolio of RNA Sequencing Tools

Retrieved on: 
Monday, May 22, 2023
Science, Other Science, Biotechnology, Nanotechnology, Research, Health, Technology, Genetics, Tissue, Methylation, Twist Bioscience, Doctor of Philosophy, RefSeq, Workflow, Martek Biosciences Corporation, NGS, RNA, Messenger, Transcriptome, Gene expression, Medicine, Silicon, Exon, Bias, Gene, Small RNA, Genome, Automation, Vaccine

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools , which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools , which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing.
  • “Twist’s RNA sequencing portfolio builds on our established NGS capabilities in genomic sequencing and methylation detection and expands into gene expression analysis, opening a new and significant market for Twist,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • The Twist RNA sequencing portfolio provides end-to-end workflows that can be used to study total RNA and measure the whole transcriptome, protein coding sequences of messenger RNA (mRNA) or custom targets.
  • Twist target enrichment for RNA leverages the performance, efficiency and sensitivity of Twist target enrichment for sequencing of RNA transcripts of interest across samples and species.

The Worldwide Nucleic Acid Sample Preparation Industry is Projected to Reach $11.2 Billion by 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 7, 2023
Biotechnology, Genetics, Health, Stem Cells, DNA, CCDS, Long-string instrument, Agilent Technologies, Workflow, QIAGEN, GENCODE, NGS, TERT, Face, Exon, Chemistry, HMW, RefSeq, OGM, UHMW, Fine chemical, Vaccine, Tecan

and Bionano Genomics created a Long String VANTAGE, a brand-new DNA extraction automation product.

Key Points: 
  • and Bionano Genomics created a Long String VANTAGE, a brand-new DNA extraction automation product.
  • Ultra-high molecular weight (UHMW) DNA can be extracted with the instrument and used for optical genome mapping (OGM).
  • As a requirement for the sample preparation workflow at Bionano Genomics, high-quality and quantity UHMW DNA extraction is required.
  • The following are the demand drivers for the global nucleic acid sample preparation market:
    The market is expected to face some limitations due to the following challenges:

Insights on the Nucleic Acid Sample Preparation Global Market to 2032 - Increasing Use of Nucleic Acid Molecules in Various Therapeutic Areas Fuels Growth

Retrieved on: 
Wednesday, February 8, 2023
DNA, CCDS, Long-string instrument, Agilent Technologies, Workflow, QIAGEN, GENCODE, NGS, TERT, Face, Research, Exon, Chemistry, HMW, RefSeq, OGM, UHMW, Fine chemical, Tecan

In 2021, the North America nucleic acid sample preparation market dominated the global market with a 46.99% market share, and it is expected to hold its dominance throughout the forecast period 2022-2032.

Key Points: 
  • In 2021, the North America nucleic acid sample preparation market dominated the global market with a 46.99% market share, and it is expected to hold its dominance throughout the forecast period 2022-2032.
  • However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 12.01% during the forecast period 2022-2032.
  • As a requirement for the sample preparation workflow at Bionano Genomics, high-quality and quantity UHMW DNA extraction is required.
  • Increased demand for high-quality reagents, kits, and related items has resulted from advancements in the nucleic acid sample preparation procedure.

Twist Bioscience Launches Exome 2.0 for Genomics Research

Retrieved on: 
Wednesday, October 20, 2021
Technology, Medical Devices, Genetics, Nanotechnology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Lists of diseases, Twist, Silicon, Doctor of Philosophy, Gene, Diagnosis, NASDAQ, CCDS, Genome, Genetics, Degenerative disease, GENCODE, Multimedia, Genomics, Catholic University of Leuven (1834–1968), Inherited disorders of trafficking, CEO, Human, Twist Bioscience, Workflow, ClinVar, RefSeq, Exome, Martek Biosciences Corporation, Fine chemical, Vaccine, Twist Exome 2.0, Twist Bioscience Corporation, TWIST EXOME 2.0, TWIST BIOSCIENCE CORPORATION

Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • Twist continues to expand our portfolio of high-quality, best-in-class life science tools, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • With the launch of Exome 2.0, we now offer a complete portfolio of flexible, comprehensive exome options to support genomics researchers looking to identify the underpinnings of disease.
  • The Twist Exome 2.0 is an exome panel designed with thoughtfully curated content that includes comprehensive coverage of genes responsible for rare diseases, inherited disorders, and germline cancers in humans.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.